On May 22, 2023, Trevi Therapeutics Inc. (NASDAQ: TRVI) opened at $2.40, lower -5.00% from the last session. During the day, the shares moved up to $2.445 and dropped to $2.24 before settling in for the closing price of $2.40. Price fluctuations for TRVI have ranged from $1.43 to $4.68 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 69.60% at the time writing. With a float of $57.54 million, this company’s outstanding shares have now reached $98.61 million.
The extent of productivity of a business whose workforce counts for 25 workers is very important to gauge.
Trevi Therapeutics Inc. (TRVI) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Trevi Therapeutics Inc. is 3.63%, while institutional ownership is 82.20%. The most recent insider transaction that took place on May 11, was worth 1,624. In this transaction Chief Financial Officer of this company sold 562 shares at a rate of $2.89, taking the stock ownership to the 27,918 shares. Before that another transaction happened on Apr 11, when Company’s Chief Financial Officer sold 840 for $1.84, making the entire transaction worth $1,545. This insider now owns 26,189 shares in total.
Trevi Therapeutics Inc. (TRVI) Latest Financial update
If we go through the results of last quarter, which was made public on 3/30/2023, the company posted -$0.06 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$0.07) by $0.01. This company achieved a return on equity of -46.82. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.60% per share during the next fiscal year.
Trevi Therapeutics Inc. (NASDAQ: TRVI) Trading Performance Indicators
Check out the current performance indicators for Trevi Therapeutics Inc. (TRVI). In the past quarter, the stock posted a quick ratio of 8.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.47, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.43 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc. (TRVI)
The latest stats from [Trevi Therapeutics Inc., TRVI] show that its last 5-days average volume of 0.43 million was superior to 95776.0 than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 8.02%. Additionally, its Average True Range was 0.25.
During the past 100 days, Trevi Therapeutics Inc.’s (TRVI) raw stochastic average was set at 35.11%, which indicates a significant increase from 3.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.24% in the past 14 days, which was lower than the 89.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.36, while its 200-day Moving Average is $2.40. Now, the first resistance to watch is $2.40. This is followed by the second major resistance level at $2.53. The third major resistance level sits at $2.61. If the price goes on to break the first support level at $2.20, it is likely to go to the next support level at $2.12. The third support level lies at $1.99 if the price breaches the second support level.
Trevi Therapeutics Inc. (NASDAQ: TRVI) Key Stats
There are currently 60,070K shares outstanding in the company with a market cap of 134.13 million. Presently, the company’s annual sales total 0 K according to its annual income of -29,150 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -6,400 K.
